Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293497218> ?p ?o ?g. }
- W4293497218 endingPage "678" @default.
- W4293497218 startingPage "671" @default.
- W4293497218 abstract "The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6–11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable. The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years. Demographic and clinical data of children aged 6–11 years, affected by moderate-to-severe AD and treated with dupilumab, were retrospectively collected from 24 dermatological and paediatric referral centres. Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 weeks. Disease severity was assessed at baseline and after week 2 (W2), W4 and W16 of dupilumab therapy using Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS) and Sleep NRS (S-NRS) and Children’s Dermatology Life Quality Index (c-DLQI) score. A total of 55 AD children (24 males [43.64%], 31 females [56.36%]; mean age 9.35 ± 1.75 years) were included. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to W16 of treatment with dupilumab. In particular, at W16 the proportion of patients achieving EASI75 was 74.54%. Moreover, at the same timepoint a significant mean percentage reduction for P-NRS, S-NRS and c-DLQI was also observed (68.39%, 70.22% and 79.03%, respectively). Our real-life data seem to confirm the effectiveness of dupilumab in paediatric patients on all disease aspects, including extent and severity of signs, intensity of symptoms, sleep and QoL, with a good safety profile." @default.
- W4293497218 created "2022-08-29" @default.
- W4293497218 creator A5001379149 @default.
- W4293497218 creator A5002336115 @default.
- W4293497218 creator A5005897842 @default.
- W4293497218 creator A5008845384 @default.
- W4293497218 creator A5009455869 @default.
- W4293497218 creator A5010568917 @default.
- W4293497218 creator A5013117510 @default.
- W4293497218 creator A5014869039 @default.
- W4293497218 creator A5017062027 @default.
- W4293497218 creator A5017503952 @default.
- W4293497218 creator A5018470862 @default.
- W4293497218 creator A5019042796 @default.
- W4293497218 creator A5035021264 @default.
- W4293497218 creator A5037063477 @default.
- W4293497218 creator A5039928844 @default.
- W4293497218 creator A5041586676 @default.
- W4293497218 creator A5041854258 @default.
- W4293497218 creator A5044096444 @default.
- W4293497218 creator A5045355563 @default.
- W4293497218 creator A5049817982 @default.
- W4293497218 creator A5051301517 @default.
- W4293497218 creator A5051487753 @default.
- W4293497218 creator A5053740932 @default.
- W4293497218 creator A5054838950 @default.
- W4293497218 creator A5055890499 @default.
- W4293497218 creator A5057684376 @default.
- W4293497218 creator A5059830636 @default.
- W4293497218 creator A5063124211 @default.
- W4293497218 creator A5067545038 @default.
- W4293497218 creator A5067671033 @default.
- W4293497218 creator A5067678368 @default.
- W4293497218 creator A5069686389 @default.
- W4293497218 creator A5073190879 @default.
- W4293497218 creator A5074694529 @default.
- W4293497218 creator A5078368275 @default.
- W4293497218 creator A5084285371 @default.
- W4293497218 creator A5091206637 @default.
- W4293497218 creator A5091751855 @default.
- W4293497218 date "2022-08-27" @default.
- W4293497218 modified "2023-10-10" @default.
- W4293497218 title "Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study" @default.
- W4293497218 cites W2025817860 @default.
- W4293497218 cites W2059510873 @default.
- W4293497218 cites W2142327072 @default.
- W4293497218 cites W2310768613 @default.
- W4293497218 cites W2411361269 @default.
- W4293497218 cites W2555680885 @default.
- W4293497218 cites W2610814011 @default.
- W4293497218 cites W2751469248 @default.
- W4293497218 cites W2771011851 @default.
- W4293497218 cites W2937103106 @default.
- W4293497218 cites W2947318731 @default.
- W4293497218 cites W2953475162 @default.
- W4293497218 cites W2980196021 @default.
- W4293497218 cites W3010287828 @default.
- W4293497218 cites W3027152065 @default.
- W4293497218 cites W3036639957 @default.
- W4293497218 cites W3087781368 @default.
- W4293497218 cites W3112462352 @default.
- W4293497218 cites W3119334612 @default.
- W4293497218 cites W3135321535 @default.
- W4293497218 cites W3138900327 @default.
- W4293497218 cites W3177432403 @default.
- W4293497218 cites W3182829909 @default.
- W4293497218 cites W3185917076 @default.
- W4293497218 cites W3212848802 @default.
- W4293497218 cites W4210971299 @default.
- W4293497218 cites W4286213240 @default.
- W4293497218 doi "https://doi.org/10.1007/s40272-022-00531-0" @default.
- W4293497218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36028611" @default.
- W4293497218 hasPublicationYear "2022" @default.
- W4293497218 type Work @default.
- W4293497218 citedByCount "13" @default.
- W4293497218 countsByYear W42934972182022 @default.
- W4293497218 countsByYear W42934972182023 @default.
- W4293497218 crossrefType "journal-article" @default.
- W4293497218 hasAuthorship W4293497218A5001379149 @default.
- W4293497218 hasAuthorship W4293497218A5002336115 @default.
- W4293497218 hasAuthorship W4293497218A5005897842 @default.
- W4293497218 hasAuthorship W4293497218A5008845384 @default.
- W4293497218 hasAuthorship W4293497218A5009455869 @default.
- W4293497218 hasAuthorship W4293497218A5010568917 @default.
- W4293497218 hasAuthorship W4293497218A5013117510 @default.
- W4293497218 hasAuthorship W4293497218A5014869039 @default.
- W4293497218 hasAuthorship W4293497218A5017062027 @default.
- W4293497218 hasAuthorship W4293497218A5017503952 @default.
- W4293497218 hasAuthorship W4293497218A5018470862 @default.
- W4293497218 hasAuthorship W4293497218A5019042796 @default.
- W4293497218 hasAuthorship W4293497218A5035021264 @default.
- W4293497218 hasAuthorship W4293497218A5037063477 @default.
- W4293497218 hasAuthorship W4293497218A5039928844 @default.
- W4293497218 hasAuthorship W4293497218A5041586676 @default.
- W4293497218 hasAuthorship W4293497218A5041854258 @default.
- W4293497218 hasAuthorship W4293497218A5044096444 @default.
- W4293497218 hasAuthorship W4293497218A5045355563 @default.
- W4293497218 hasAuthorship W4293497218A5049817982 @default.